Table 6.
Performance of PET/CT and cePET/CT in tumors, sites of disease, and clinical questions whose diagnostic results were significantly different between the two imaging modalities
| PET/CT | cePET/CT | |
|---|---|---|
|
Tumor type |
|
|
|
Head and neck cancer |
|
|
| Sensitivity (%) |
71.33 (63.64–77.97) |
82.67 (75.81–87.89) |
| Specificity (%) |
46.30 (33.69–59.39) |
48.15 (35.39–61.15) |
|
Gastrointestinal cancer
a
|
|
|
| Sensitivity (%) |
71.25 (60.54–80.01) |
95.00 (87.84–98.04) |
| Specificity (%) |
84.21 (62.43–94.48) |
89.47 (68.61–97.06) |
|
Site of disease |
|
|
|
Abdomen |
|
|
| Sensitivity (%) |
97.53 (91.44–99.32) |
92.59 (84.77–96.56) |
| Specificity (%) |
46.15 (23.21–70.86) |
92.31 (66.69–98.63) |
|
Questions |
|
|
|
Restaging
b
|
|
|
| Sensitivity (%) |
83.96 (75.81–89.74) |
96.23 (90.70–98.52) |
| Specificity (%) | 78.37 (52.33–92.50) | 78.57 (52.41–92.43) |
Estimated parameters corresponding to each technique are presented with 95% confidence interval within parentheses.
aIncluding esophageal, gastric, and colorectal cancer.
bSuspected relapse or patients with potentially resectable metastatic disease.
PET, positron emission tomography; CT, computed tomography; cePET/CT, contrast-enhanced PET/ CT.